The prognostic value of Smad4 mRNA in patients with prostate cancer

详细信息    查看全文

• 作者：Da-Tian Zhang (1)
  Jian-Guo Shi (1)
  Yian Liu (1)
  Hua-Mao Jiang (1)
  
• 关键词：Prostate cancer ; Smad4 ; mRNA ; Biomarker
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：35
• 期：4
• 页码：3333-3337
• 全文大小：126 KB
• 参考文献：1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-6. CrossRef
  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-00. CrossRef
  3. Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56. CrossRef
  4. Zhang H, Qi C, Wang A, Li L, Xu Y. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer. Tumor Biol. 2013. doi:10.1007/s13277-013-1268-z .
  5. Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 2013;32:77. CrossRef
  6. Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science. 2002;296:1646-. CrossRef
  7. Attisano L, Tuen L-HS. The Smads. Genome Biol. 2001;2:3010.1-. CrossRef
  8. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 2003;13:685-00. CrossRef
  9. Itoh S, Itoh F, Goumans MJ, Ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem. 2000;267:6954-7. CrossRef
  10. Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol. 2002;191:1-6. CrossRef
  11. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene. 1997;15:1111-. CrossRef
  12. Yang L, You S, Kumar V, Zhang C, Cao Y. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. J Exp Clin Cancer Res. 2012;31:40. CrossRef
  13. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res. 2012;31:32. CrossRef
  14. Zhou Y, Su Z, Huang Y, Sun T, Chen S, Wu T, et al. The Zfx gene is expressed in human gliomas and is important in the proliferation and apoptosis of the human malignant glioma cell line U251. J Exp Clin Cancer Res. 2011;30:114. CrossRef
  15. Li Z, Tanaka H, Galiano F, Glass J. Anticancer activity of the iron facilitator LS081. J Exp Clin Cancer Res. 2011;30:34. CrossRef
  16. Kanamori M, Sano A, Yasuda T, Hori T, Suzuki K. Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. J Exp Clin Cancer Res. 2012;31:100. CrossRef
  17. Piscitelli P, Barba M, Crespi M, Di Maio M, Santoriello A, D’Aiuto M, et al. The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records. J Exp Clin Cancer Res. 2012;31:96. CrossRef
  18. Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634. CrossRef
  19. Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14. CrossRef
  20. Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS ONE. 2013;8:e58170. CrossRef
  21. Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366. CrossRef
  22. Maio M, Ascierto P, Testori A, Ridolfi R, Bajetta E, Queirolo P, et al. The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res. 2012;31:91. CrossRef
  23. Solivetti FM, Elia F, Graceffa D, Di Carlo A. Ultrasound morphology of inguinal lymph nodes may not herald an associated pathology. J Exp Clin Cancer Res. 2012;31:88. CrossRef
  24. Ozasa R, Ohno J, Iwahashi T, Taniguchi K. Tumor-induced lymphangiogenesis in cervical lymph nodes in oral melanoma-bearing mice. J Exp Clin Cancer Res. 2012;31:83. CrossRef
  25. Bartolo M, Zucchella C, Pace A, De Nunzio AM, Serrao M, Sandrini G, et al. Improving neuro-oncological patients care: basic and practical concepts for nurse specialist in neuro-rehabilitation. J Exp Clin Cancer Res. 2012;31:82. CrossRef
  26. Cuozzo F, Raciti M, Bertelli L, Parente R, Di Renzo L. Pro-death and pro-survival properties of ouabain in U937 lymphoma derived cells. J Exp Clin Cancer Res. 2012;31:95. CrossRef
  27. Hsu CM, Lin PM, Wang YM, Chen ZJ, Lin SF, Yang MY. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumor Biol. 2012;33(6):1933-2. CrossRef
  28. Pandith AA, Siddiqi MA. Burden of cancers in the valley of Kashmir: 5?year epidemiological study reveals a different scenario. Tumor Biol. 2012;33(5):1629-7. CrossRef
  29. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, et al. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumor Biol. 2012;33(4):967-8. CrossRef
  30. Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E. Targeting the endothelin axis in prostate carcinoma. Tumor Biol. 2012;33(2):421-. CrossRef
  
• 作者单位：Da-Tian Zhang (1)
  Jian-Guo Shi (1)
  Yian Liu (1)
  Hua-Mao Jiang (1)
  
  1. Department of Urology, First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121001, China
  
• ISSN：1423-0380

文摘

The tumor suppressor gene Smad4 has been localized to chromosome 18q21.1 and is a member of the Smad family that mediates the transforming growth factor β signaling pathway suppressing epithelial cell growth. However, variable expression of Smad4 messenger RNA (mRNA) has been reported, with a loss in some cancers and increased expression in others. The aim of the present study was to investigate the Smad4 mRNA expression in prostate cancer tissues and adjacent noncancerous tissues and its potential relevance to clinicopathological variables and prognosis. The expression change of Smad4 mRNA was detected by using real-time quantitative reverse transcriptase-polymerase chain reaction analysis. The data showed that the Smad4 mRNA expression level in prostate cancer tissues was significantly lower than those in noncancerous tissues. The results indicated that the low expression of Smad4 mRNA in prostate cancer was associated with lymph node metastasis, preoperative prostate-specific antigen (PSA), and Gleason score. Kaplan–Meier survival analysis showed that patients with high Smad4 mRNA expression have longer biochemical recurrence-free survival time compared to patients with low Smad4 mRNA expression. Multivariate analysis revealed that Smad4 mRNA expression was an independent predictor of biochemical recurrence-free survival. Our results emphasize that Smad4 mRNA can be used as a predictive biomarker.